SCHEDULE 13G/A 0001580642-24-006742 0001442891 XXXXXXXX LIVE 3 Common Stock, $0.001 par value per share 12/31/2024 0001725160 Zentalis Pharmaceuticals, Inc. 98943L107 10275 Science Center Dr., Suite 200 San Diego CA 92121 Rule 13d-1(b) Eventide Asset Management, LLC DE 4475054.00 0.00 4475054.00 0.00 4475054.00 N 6.28 IA Finny Kuruvilla, M.D., Ph. D. X1 0.00 4475054.00 0.00 4475054.00 4475054.00 N 6.28 HC IN Robin C. John X1 0.00 4475054.00 0.00 4475054.00 4475054.00 N 6.28 HC IN Zentalis Pharmaceuticals, Inc. 10275 Science Center Dr., Suite 200, San Diego, California, 92121 Eventide Asset Management, LLC Finny Kuruvilla, M.D., Ph.D. Robin C. John Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110 Eventide: Delaware Kuruvilla: United States John: United States N IA HC Eventide: 4,475,054 Kuruvilla: 4,475,054 John: 4,475,054 Eventide: 6.28% Kuruvilla: 6.28% John: 6.28% Eventide: 4,475,054 Kuruvilla: 0 John: 0 Eventide: 0 Kuruvilla: 4,475,054 John: 4,475,054 Eventide: 4,475,054 Kuruvilla: 0 John: 0 Eventide: 0 Kuruvilla: 4,475,054 John: 4,475,054 Y N As of December 31, 2024, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 4,475,054 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund, which are registered investment companies, and Eventide separately managed accounts, (the "Accounts"). As of December 31, 2024, the Eventide Gilead Fund held 1,640,469 shares of the Issuer's Common Stock, representing 2.30% of the Issuer's outstanding Common Stock, the Eventide Healthcare & Life Sciences Fund held 2,825,120 shares of the Issuer's Common Stock, representing 3.97% of the Issuer's outstanding Common Stock, and Eventide's separately managed accounts held 9,465 shares of the Issuer's Common Stock, representing 0.01% of the Issuer's outstanding Common Stock, which together represents 6.28% of the Issuer's outstanding Common Stock. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities. EX 1 Eventide Asset Management, LLC /s/ Peter J. Luiso 02/10/2025 Finny Kuruvilla, M.D., Ph. D. /s/ Finny Kuruvilla, M.D., Ph. D. 02/10/2025 Robin C. John /s/ Robin C. John 02/10/2025